postdoctoral fellowship medical education communication publication planning

PharmaWrite at the 12th Annual Meeting of ISMPP


Compiled for you by PharmaWrite.
At the 12th annual meeting of the International Society of Medical Publication Professionals (ISMPP), many of the panel discussions looked to the future to identify new trends and practices that will significantly impact publications in the next few years. One of the important trends recognized was the increasing value being placed on health economics and outcomes research (HEOR).

The growing importance and focus on health economics and outcomes research (HEOR) is the result of changes in drug reimbursement policies. Before these changes, HEOR was often placed on the bottom rung of the evidence hierarchy. This was because health outcomes and cost-effectiveness data were considered "less robust" than data from clinical trials. However, as noted, this view is rapidly changing.

HEOR publication planners can now help underscore the value of HEOR analyses in assessing how effectively our healthcare dollars are spent by partnering with clinicians who know the methodologies and can bring key opinion leaders (or "KOLs") on board.

Since HEOR/real world evidence (RWE) studies are observations of treatment effects where the researcher has no control over the subsequent medical management of the patient, publication professionals should always be aware of the potential issues that can arise in these studies that are not common in randomized controlled trials (or "RCTs").

Potential issues associated with real world evidence include:

For your convenience, and for your reference, the PharmaWrite staff has compiled a detailed meeting summary of the ISMPP event, including session descriptions, key takeaways, and valuable speaker comments and quotes. The summary includes valuable in-depth information, like the material presented here, on all of the topics discussed at ISMPP. Please fill out the form below to request this comprehensive summary.